A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis

BACKGROUND: Toremifene (TOR) is a selective oestrogen receptor modulator (SERM) and has comparable efficacy to that of tamoxifen (TAM) in breast cancer patients. Herein, we compared the safety of TOR to that of TAM in the adjuvant treatment of premenopausal breast cancer. METHODS: This was a prospec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Hong, Jin, Huang, Jiahui, Shen, Lili, Zhu, Siji, Gao, Weiqi, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Chen, Xiaosong, Shen, Kunwei
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7364473/
https://ncbi.nlm.nih.gov/pubmed/32677982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07156-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars